Rampart IC, a medical technology company developing market-leading radiation safety and orthopedic protection solutions for the interventional suite, announced the successful completion of its $21.6M Series B financing round. The round was...
Rampart IC, a medical technology company developing market-leading radiation safety and orthopedic protection solutions for the interventional suite, announced the successful completion of its $21.6M Series B financing round. The round was...
Whether you’re focused on clinical care, innovation, or training the next generation, there’s something here to support your clinical, research, and career goals,” said SCAI President James B. Hermiller, MD, MSCAI.
Whether you’re focused on clinical care, innovation, or training the next generation, there’s something here to support your clinical, research, and career goals,” said SCAI President James B. Hermiller, MD, MSCAI.
This document draws on global clinical data and real-world evidence to evaluate the impact of a cardiac ablation SDD strategy on patient safety, access, operational efficiencies, and healthcare costs. It also outlines best practices based on...
This document draws on global clinical data and real-world evidence to evaluate the impact of a cardiac ablation SDD strategy on patient safety, access, operational efficiencies, and healthcare costs. It also outlines best practices based on...
Using the model to analyze patients’ ECG results could allow cardiologists to prioritize the highest-risk patients to bring them in sooner for an appointment and treatment before symptoms begin or exacerbate.
Using the model to analyze patients’ ECG results could allow cardiologists to prioritize the highest-risk patients to bring them in sooner for an appointment and treatment before symptoms begin or exacerbate.
The Heart Rhythm Society (HRS) releases a framework outlining criteria for establishing an Atrial Fibrillation (AF) Center of Excellence (CoE) and key operational standards to provide multidisciplinary care for AF patients.
The Heart Rhythm Society (HRS) releases a framework outlining criteria for establishing an Atrial Fibrillation (AF) Center of Excellence (CoE) and key operational standards to provide multidisciplinary care for AF patients.
EFEMORAL I is a first-in-human clinical trial evaluating the performance of the Efemoral Vascular Scaffold System (EVSS) for the treatment of patients suffering symptomatic peripheral arterial occlusive disease from atherosclerosis of the...
EFEMORAL I is a first-in-human clinical trial evaluating the performance of the Efemoral Vascular Scaffold System (EVSS) for the treatment of patients suffering symptomatic peripheral arterial occlusive disease from atherosclerosis of the...
The PerQseal® Elite vascular closure system is a sutureless and fully bioresorbable large-bore vessel closure device. The company plans to launch the product in select European markets this summer.
The PerQseal® Elite vascular closure system is a sutureless and fully bioresorbable large-bore vessel closure device. The company plans to launch the product in select European markets this summer.
The first patient in its ELITE-BTK pivotal trial was treated by Dr. Brian DeRubertis, FACS, Chief of the Division of Vascular & Endovascular Surgery at NewYork-Presbyterian and Weill Cornell Medicine in New York City.
The first patient in its ELITE-BTK pivotal trial was treated by Dr. Brian DeRubertis, FACS, Chief of the Division of Vascular & Endovascular Surgery at NewYork-Presbyterian and Weill Cornell Medicine in New York City.
“Patients at higher risk for mortality and morbidity associated with high blood pressure are the core of the population we are actively enrolling in the BACKBEAT global pivotal study of hypertensive pacemaker-indicated patients in...
“Patients at higher risk for mortality and morbidity associated with high blood pressure are the core of the population we are actively enrolling in the BACKBEAT global pivotal study of hypertensive pacemaker-indicated patients in...
Camzyos is an FDA-approved cardiac myosin inhibitor for the treatment of adults with symptomatic New York Heart Association (NYHA) Class II-III obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.(1)
Camzyos is an FDA-approved cardiac myosin inhibitor for the treatment of adults with symptomatic New York Heart Association (NYHA) Class II-III obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.(1)
Rampart IC, a medical technology company developing market-leading radiation safety and orthopedic protection solutions for the interventional suite, announced the successful completion of its $21.6M Series B financing round. The round was...
Rampart IC, a medical technology company developing market-leading radiation safety and orthopedic protection solutions for the interventional suite, announced the successful completion of its $21.6M Series B financing round. The round was...
Whether you’re focused on clinical care, innovation, or training the next generation, there’s something here to support your clinical, research, and career goals,” said SCAI President James B. Hermiller, MD, MSCAI.
Whether you’re focused on clinical care, innovation, or training the next generation, there’s something here to support your clinical, research, and career goals,” said SCAI President James B. Hermiller, MD, MSCAI.
This document draws on global clinical data and real-world evidence to evaluate the impact of a cardiac ablation SDD strategy on patient safety, access, operational efficiencies, and healthcare costs. It also outlines best practices based on...
This document draws on global clinical data and real-world evidence to evaluate the impact of a cardiac ablation SDD strategy on patient safety, access, operational efficiencies, and healthcare costs. It also outlines best practices based on...
“If you have a heart attack in the morning, you are more likely to have fatal arrhythmias, heart failure, and you’re more likely to die from it. The question we asked is ‘Why?’” said Holger Eltzschig, MD, PhD.
“If you have a heart attack in the morning, you are more likely to have fatal arrhythmias, heart failure, and you’re more likely to die from it. The question we asked is ‘Why?’” said Holger Eltzschig, MD, PhD.
Using the model to analyze patients’ ECG results could allow cardiologists to prioritize the highest-risk patients to bring them in sooner for an appointment and treatment before symptoms begin or exacerbate.
Using the model to analyze patients’ ECG results could allow cardiologists to prioritize the highest-risk patients to bring them in sooner for an appointment and treatment before symptoms begin or exacerbate.
The Heart Rhythm Society (HRS) releases a framework outlining criteria for establishing an Atrial Fibrillation (AF) Center of Excellence (CoE) and key operational standards to provide multidisciplinary care for AF patients.
The Heart Rhythm Society (HRS) releases a framework outlining criteria for establishing an Atrial Fibrillation (AF) Center of Excellence (CoE) and key operational standards to provide multidisciplinary care for AF patients.
EFEMORAL I is a first-in-human clinical trial evaluating the performance of the Efemoral Vascular Scaffold System (EVSS) for the treatment of patients suffering symptomatic peripheral arterial occlusive disease from atherosclerosis of the...
EFEMORAL I is a first-in-human clinical trial evaluating the performance of the Efemoral Vascular Scaffold System (EVSS) for the treatment of patients suffering symptomatic peripheral arterial occlusive disease from atherosclerosis of the...
The PerQseal® Elite vascular closure system is a sutureless and fully bioresorbable large-bore vessel closure device. The company plans to launch the product in select European markets this summer.
The PerQseal® Elite vascular closure system is a sutureless and fully bioresorbable large-bore vessel closure device. The company plans to launch the product in select European markets this summer.
The first patient in its ELITE-BTK pivotal trial was treated by Dr. Brian DeRubertis, FACS, Chief of the Division of Vascular & Endovascular Surgery at NewYork-Presbyterian and Weill Cornell Medicine in New York City.
The first patient in its ELITE-BTK pivotal trial was treated by Dr. Brian DeRubertis, FACS, Chief of the Division of Vascular & Endovascular Surgery at NewYork-Presbyterian and Weill Cornell Medicine in New York City.
“Patients at higher risk for mortality and morbidity associated with high blood pressure are the core of the population we are actively enrolling in the BACKBEAT global pivotal study of hypertensive pacemaker-indicated patients in...
“Patients at higher risk for mortality and morbidity associated with high blood pressure are the core of the population we are actively enrolling in the BACKBEAT global pivotal study of hypertensive pacemaker-indicated patients in...
